Activated T-Cell and Bispecific Antibody Immunotherapy for High-Risk Breast Cancer

Publisher： Karger

E-ISSN： 1421-9662|105|3|130-136

ISSN： 0001-5792

Source： Acta Haematologica, Vol.105, Iss.3, 2001-07, pp. : 130-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy with the trifunctional anti‐CD20 x anti‐CD3 antibody FBTA05 (Lymphomun) in paediatric high‐risk patients with recurrent CD20‐positive B cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 90-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Chemotherapy in High-Risk Primary Breast Cancer

By  

Oncology Research and Treatment, Vol. 25, Iss. 2, 2002-05 ,pp. : 112-120

Karger

Access to resources Recommend Favorite

High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy

By Balleine Rosemary L.   Wilcken Nicholas R.  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 235-240

Adis International

Access to resources Recommend Favorite

Treatment of High-Risk Peripheral T-Cell Lymphomas other than Anaplastic Large-Cell Lymphoma with a Dose-Intensified CHOP Regimen Followed by High-Dose Chemotherapy

By  

Acta Haematologica, Vol. 116, Iss. 2, 2006-08 ,pp. : 90-95

Karger

Access to resources Recommend Favorite

Immunotherapy in Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 6, 2016-05 ,pp. : 335-345

Karger

Access to resources Recommend Favorite